Pembrolizumab approved for use in EU as first-line treatment in adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer

Approval is based on results from the phase 3 KEYNOTE-177 trial, in which pembrolizumab monotherapy reduced the risk of disease progression or death by vs chemotherapy (HR 0.60, 95% CI 0.45-0.80). This is the first anti-PD-1/L1 therapy approved in the EU for these patients.

Source:

Biospace Inc.